Low-dose infusion of recombinant tissue-type plasminogen activator in healthy volunteers to investigate the biodistribution of t-PA in the early phase of infusion

Fibrinolysis and Proteolysis

Volumn 11, Issue 1, 1997, Pages 21-27

  Van Griensven, J M T ^a   Huisman, L G M ^a   Schoemaker, H C ^a   Kluft, C ^a   Cohen, A F ^b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

EID: 0031002650     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80005-7     Document Type: Article

References (27)

1. Cheng X, Back O, Nilsson T K, Nylander Lundqvist E, Pohl G, Wallen P. Binding of tissue plasminogen activator to human endothelial cells. Biochem J 1992; 287: 407-413.
2. Barnathan E S, Kuo A, van der Keyl H, McCrae K R, Larsen G R, Cines D B. Tissue-type plasminogen activator binding to human endothelial cells. J Biol Chem 1988; 263: 7792-7799.
3. Hajjar K A, Hamel N M, Harpel P C, Nachman R L. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest 1987; 80: 1712-1719.
4. Thompson S G, Kienast J, Pyke S D M, Haverkate F, van de Loo J C W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-641.
5. Gram J, Jespersen J, Kluft C, Rijken D C. On the usefulness of fibrinolysis variables in characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149-153.
6. Jansson H, Nilsson T K, Olofsson B O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991 ; 12: 157-161.
7. Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery diseases. A 7-year follow up. Circulation 1993; 88: 2030-2034.
8. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
9. Ridker P M, Hennekens C H, Stampfer M J, Manson J E, Vaughan D E. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
10. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-682.
11. ISIS-3 (third international study of infarct survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
12. National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1992; 1: 203-207.
13. Williams D O, Borer J, Braunwald E et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338-346.
14. Van der Werf F, Ludbrook P A, Bergmann S R et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. New Engl J Med 1984; 310: 609-613.
15. Garabedian H D, Gold H K, Leinbach R C, Yasuda T, Johns J A, Collen D. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986; 58:673-679.
16. Emeis J J. Mechanisms involved in short-term changes in blood levels of t-PA. In: Kluft C, ed. Tissue-type plasminogen activator (t-PA): Physiological and clinical aspects. Boca Raton, CRC Press, Inc., 1988:21-35.
17. van den Brug P J M, Dooijewaard G, van Vliet M, Mosterd W L, Kluft C, Huisveld I A. Differences in u-PA and t-PA increase during acute exercise: relation with exercise parameters. Thromb Haemost 1994; 71: 236-239.
18. Prowse C V, Farrugia A, Boulton F E et al. A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemost 1984; 51: 110-114.
19. De Boer A, Kluft C, Dooijewaard G et al. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost 1992; 68: 550-555.
20. Wejkum L, Rosen S, Sörskog L, Brandt B, Chmielewska J. Blood sampling and determination of tissue plasminogen activator activity with COA-SET R t-PA. Fibrinolysis 1990; 4: 152-154.
21. Rânby M, Nguyen G, Scarabin P Y, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 1989; 61: 409-414.
22. Emeis J J. The control of t-PA and PAI-1 secretion from the vessel wall. Vase Med Rev 1995; 6: 153-166.
23. Hajjar K A, Hamel N M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990; 265: 2908-2916.
24. Kluft C. Endothelium as a source of tissue-type plasminogen activator (t-PA for fibrinolysis). In: Warren J B, ed. The endothelium. An introduction to current research. Wiley-Liss, New York, 1990: 129-139.
25. Hajjar K A, Jacovina A T, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with Annexin II. J Biol Chem 1994; 269: 21191-21197.
26. Cesarman G M, Guevara C A, Hajjar K A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
27. Kluft C, Potter van Loon B J, de Maat M P M. Insulin resistance and changes in haemostatic variables. Fibrinolysis 1992; 6: 11-16.